Allelic losses in oligodendroglial and oligodendroglioma-like neoplasms: analysis using microsatellite repeats and polymerase chain reaction.

Department of Pathology, Vanderbilt Medical School, Nashville, Tenn 37232, USA.
Archives of pathology & laboratory medicine (Impact Factor: 2.88). 01/2004; 127(12):1573-9. DOI: 10.1043/1543-2165(2003)127<1573:ALIOAO>2.0.CO;2
Source: PubMed

ABSTRACT Oligodendroglial tumors are heterogenous neoplasms with histologic features shared with other central nervous system tumors, such as dysembryoplastic neuroepithelial tumors.
We examined a series of tumors, identified as possessing oligodendroglial components at the time of intraoperative examination, to see if molecular subsets based on the oligodendroglial component could be recognized.
DNA was extracted from fresh brain tumor tissue and corresponding peripheral blood or normal tissues. Genotypes for multiple loci were determined by polymerase chain reaction amplification using fluorescent-labeled primers for markers on chromosomes 1p, 17p, and 19q.
Of the 12 oligodendrogliomas, 6 (60%) of 10 informative cases for 1p exhibited loss of heterozygosity (LOH). Six (50%) of 12 informative cases for 19q exhibited LOH. Each case also showed LOH at 1p. Three (25%) of 12 informative cases exhibited LOH at 17p for the dinucleotide repeat within the TP53 gene. In oligoastrocytomas, none of 4 informative cases showed LOH at 1p, 1 (25%) showed LOH at 19q, and 2 (50%) at 17p. One case also displayed microsatellite instability at 3 of 8 markers. In the 3 anaplastic oligodendrogliomas, 1 was not informative for 1p and none of the informative tumors exhibited LOH at 1p or 17p; 1 case (33%) exhibited LOH at 19q. Of the 14 informative anaplastic oligoastrocytomas, LOH was seen in 5 (36%) at both 1p and 19q and in 2 (14%) at 17p. Those with allelic loss at TP53 were astrocytoma predominant. No dysembryoplastic neuroepithelial tumors exhibited LOH at any marker on 1p, 17p, or 19q.
These findings suggest that routine screening for allelic losses, in samples intraoperatively determined to have an oligodendroglial component, will reveal prognostically or therapeutically relevant information in the majority of cases.

  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: AIMS: Combined deletion of the whole chromosomal arms 1p and 19q is a frequent event in oligodendroglial tumours. Recent identification of recurrent mutations in CIC on 19q and FUBP1 on 1p and their mutational patterns suggest a loss of function of the respective proteins. Surprisingly, oligoastrocytomas harbouring identical genetic characteristics regarding 1p/19q co-deletion and frequent IDH1/2 mutations have been shown to carry CIC mutations in a significantly lower number of cases. The present study investigates whether epigenetic modification may result in silencing of CIC. METHODS: Since IDH1/2 mutation mediated DNA hypermethylation is a prominent feature of these tumours, we analyzed a set of CIC wild-type oligoastrocytomas and other diffuse gliomas with regard to 1p/19q status for presence of CIC-associated CpG-island methylation by methylation-specific PCR. RESULTS: Both methylation specific PCR and subsequent bisulfite-sequencing of selected cases revealed an unmethylated status in all samples. CONCLUSION: Despite the hypermethylator- phenotype in IDH1/2 mutant tumours and recent detection of gene silencing particularly on retained alleles in oligodendendroglial tumours, hypermethylation of CIC-associated CpG-islands does not provide an alternative mechanism of functional CIC protein abrogation.
    Neuropathology and Applied Neurobiology 03/2013; DOI:10.1111/nan.12045 · 4.97 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: La meilleure connaissance de l'histoire spontanée des gliomes de grade II de l'Organisation mondiale de la santé (OMS), à savoir la croissance régulière, l'infiltration le long des faisceaux de substance blanche et surtout le risque de transformation anaplasique – menaçant ainsi les pronostics fonctionnel et vital – associée à une minimisation des risques de traitements, a transformé l'attitude abstentionniste « classique » en une attitude résolument thérapeutique. Le but est dorénavant de tendre vers l'élaboration de véritables stratégies thérapeutiques adaptées à chaque patient, à savoir de déterminer l'ordre et le moment de chacun des traitements (1 re voire 2 e exérèse chirurgicale, 1 re voire 2 e ligne de chimiothérapie, radiothérapie) en fonction de l'évolution tumorale (mesurée sur les images en résonance magnétiques régulières de contrôle), de l'état clinique et neuropsychologique ainsi que de l'organisation anatomofonctionnelle cérébrale individuelle (étudiée grâce aux méthodes de cartographie), afin d'éviter la transformation maligne le plus longtemps possible tout en préservant la qualité de vie, cette tumeur survenant le plus souvent chez des patients jeunes avec une vie familiale et une activité socioprofessionnelle normales.
    01/2008; 5(3). DOI:10.1016/S0246-0378(08)46100-6
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Recent studies imply the importance of rapid and reliable diagnostic assessment of 1p/19q status in oligodendroglial tumors. To date, fluorescent in situ hybridization (FISH) is the most commonly applied technique. FISH, however, has several technical shortcomings that are suboptimal for diagnostic applications: results must be viewed in a fluorescence microscope, results are usually evaluated by a single investigator only and signal fading excludes physical archiving. Also, in gliomas, the distinction of diffusely infiltrating tumor cells from reactively altered normal tissue may be challenging in fluorescence microscopy. Dual- color chromogenic in situ hybridization (CISH) has started to replace FISH in some diagnostic tests performed in pathology. Here, we present the first single institute experience with a side- by side analysis of 1p/19q FISH and CISH in a series of 42 consecutive gliomas. FISH and CISH produced identical results for 1p and 19q in 93% of cases (n= 39/42). Discrepant results were re-evaluated by repeated FISH and a PCR- based microsatellite marker analysis for loss of heterozygosity. Re-evaluation confirmed CISH data in all three cases. We conclude that CISH is a reliable alternative in 1p/19q testing in paraffin embedded tissues likely to be more sensitive to detect 1p/19q status than FISH analysis.
    Brain Pathology 10/2012; 23(3). DOI:10.1111/bpa.12003 · 4.35 Impact Factor